Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai ImmuneOnco Raises $89 Million for Cancer Immunotherapies

publication date: Mar 25, 2021

Shanghai ImmuneOnco Biopharma completed an $89 million Series C funding led by Guangdong's Greater Homeland Bay Area Investments and Lilly Asia Ventures. Founded in 2015, ImmuneOnco has established discovery platforms that exploit two types of innate immune cells: macrophages and natural killer (NK) cells. The company has been approved to start two clinical trials: IMM01, an anti-CD47 fusion protein, was approved in China, and IMM0306, a bispecific antibody targeting CD47 and CD20, was approved in the US. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital